Trial Profile
A multicenter, double-blind, randomized, parallel group study to evaluate the safety and efficacy of sitagliptin in elderly patients with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 01 Feb 2014 Results published in the Drugs and Aging.
- 23 Mar 2011 Results published in the Current Medical Research and Opinion.
- 09 Jun 2009 Results were reported at the 69th Annual Scientific Sessions of the American Diabetes Association.